It has been suggested that GPX2 expression is tumor-stage-dependent, and upregulation of GPx2 in early-stage carcinomas might protect tumor cells from the effects of ROS on oncogenic signaling, leading to neoplastic progression. This evidence concerns the gene GPX2 and neoplasm.